Summary: Researchers have clarified a key step in Parkinson’s disease progression: a mutated form of the protein α-synuclein travels through the brain’s lymphatic drainage—the glymphatic system—before it forms the pathological clumps associated with disease. This discovery shifts attention to early, monomeric α-synuclein movement as a potential therapeutic target to slow or stop disease spread.
In experiments using fluorescently labeled α-synuclein in mice, the team observed that mutant monomeric α-synuclein spreads quickly to distant brain regions while fibrillar aggregates appear much later. These findings suggest that preventing monomer propagation or interfering with its passage through the glymphatic pathways could reduce downstream aggregation and neural damage in Parkinson’s disease.
Key Facts:
- The mutant α-synuclein protein is transported through the brain’s glymphatic (lymphatic) system prior to forming insoluble clumps.
- Fluorescent monomeric α-synuclein was detected in remote brain regions as early as two weeks after injection, indicating rapid early spread.
- Distinct α-synuclein fibrils emerged only 12 months after injection, demonstrating a substantial delay between propagation and aggregation.
Source: Tokyo Medical and Dental University
Background: Neurodegenerative diseases often involve abnormal proteins that both aggregate and spread through the brain. Clarifying whether aggregation precedes propagation—or vice versa—is critical for designing early interventions. A research team at Tokyo Medical and Dental University investigated this question for α-synuclein, a protein that normally participates in synaptic function but can misfold and form toxic aggregates in Parkinson’s disease.
Published in Cell Reports, the study focused on the mutant A53T form of α-synuclein. Instead of introducing pre-formed fibrils, the researchers used viral vectors to produce fluorescently labeled monomeric mutant α-synuclein in the orbital cortex of mice. This approach allowed monomer production across all cell types at the injection site so that any natural propagation routes—neuronal, extracellular, or lymphatic—could be observed.
Tracking the fluorescent signal over time revealed two clear phases. The monomeric mutant protein reached distant brain regions and the brain’s glymphatic pathways within two weeks. By contrast, characteristic fibrils and aggregated α-synuclein were not evident until 12 months after the initial injection. This time gap indicates that monomeric propagation precedes and likely contributes to later in situ aggregation.
To determine how α-synuclein traversed the brain, the team mapped its three-dimensional distribution and found fluorescent protein within glymphatic channels—the brain’s fluid drainage and waste-clearance routes. The glymphatic system normally clears interstitial fluid and metabolic waste, but it can also spread soluble molecules throughout the brain. The researchers also detected fluorescent α-synuclein in the extracellular matrix that surrounds neurons and subsequently inside neuronal cytosol, consistent with uptake of monomers from extracellular spaces into cells.
Microscopy at high resolution showed that propagated monomer penetrated perineuronal nets and contacted neuron surfaces before being internalized. Electron microscopy provided further evidence that, after neuronal uptake, the mutant monomeric protein could assemble into fibrils characteristic of Parkinson’s disease. Importantly, the timing and extent of aggregation varied across brain regions and did not simply reflect distance from the injection site, aligning with known regional susceptibility to α-synuclein pathology.
These observations support a propagation model distinct from the classic neuron-to-neuron transmission of pre-formed aggregates: soluble, misfolded α-synuclein monomers can distribute broadly via the brain’s lymphatic pathways and extracellular spaces, then be taken up by neurons where they eventually nucleate into fibrils. This sequence highlights two potential early intervention points—blocking monomer mobilization through the glymphatic system and preventing neuronal uptake or intracellular conversion to fibrils.
About this Parkinson’s disease research news
Author: Hitoshi Okazawa
Source: Tokyo Medical and Dental University
Contact: Hitoshi Okazawa – Tokyo Medical and Dental University
Image: The image is credited to Neuroscience News
Original Research: Open access. “Mutant α-synuclein propagates via the lymphatic system of the brain in the monomeric state” by Hitoshi Okazawa et al., Cell Reports.
Abstract
Mutant α-synuclein propagates via the lymphatic system of the brain in the monomeric state
Highlights
- Prion-like propagation of misfolded proteins is a shared pathogenic feature of many neurodegenerative diseases.
- Previous models emphasized neuron-to-neuron transfer of aggregated proteins; this work expands that view.
- The study reveals that monomeric mutant α-synuclein can travel through the brain lymphatic (glymphatic) system to reach remote regions.
- Interrupting monomeric glymphatic propagation presents a promising direction for future therapies aimed at slowing Parkinson’s disease progression.
Summary
Prion-like propagation of misfolded proteins is considered a common mechanism underlying neurodegenerative disease spread. In vivo tracing of mutant α-synuclein behavior after localized production in the mouse olfactory cortex demonstrates that monomeric mutant protein disperses rapidly to remote brain areas—within two weeks—via the glymphatic system and extracellular spaces. Subsequent incorporation into neurons leads to local aggregation and fibril formation over months. These results describe a propagation pathway distinct from aggregate-dependent neuron-to-neuron transfer and identify early monomeric spread through brain lymphatics as a target for interventions to prevent or slow Parkinson’s disease.